DANVERS, Mass., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has expanded its U.S. Food and ...
Abiomed Inc. ABMD recently announced that its Impella 2.5 heart pump has received FDA Pre-Market Approval (PMA) for use in high risk percutaneous coronary intervention (PCI) procedures. Notably, ...
At Abiomed's European headquarters in Aachen, Germany, Impella heart pumps have been developed and produced for more than 20 years to stabilize and recover the human heart. The single access procedure ...
Impella 2.5 is a miniaturised, catheter-based, intravascular blood pump that supports a patient's circulatory system. It provides continuous forward flow to increase overall cardiac output, unload ...
NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...
The Heart Hospital of Northwest Texas Healthcare System has been recognized by Abiomed for its achievement of 200 Impella procedures, according to a news release. This life-changing procedure has ...
A pricey high-tech pump that maintains blood flow during heart procedures could be more dangerous to patients than its low-tech predecessor, a pair of recent studies finds. The Impella device is ...
DANVERS, Mass., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has expanded its U.S. Food and ...
AACHEN, Germany--(BUSINESS WIRE)--Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback